This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Diamond, E. J. Articles by Hollander, V. P. Search for Related Content PubMed PubMed Citation Articles by Diamond, E. J. Articles by Hollander, V. P.

Estradiol Binding in Ovariectomy-responsive and -nonresponsive Rat Mammary Carcinoma¹

Research Institute of the Hospital for Joint Diseases, Mount Sinai School of Medicine, New York, New York 10035

MTW9, a transplantable mammary tumor in Wistar-Furth rats, is dependent upon high levels of serum prolactin for growth. The mammary tumor can be maintained by coimplantation with a pituitary mammosomatotropic tumor (MTW9-MtT) or by chronic perphenazine administration (MTW9-P). MTW9-MtT does not regress after ovariectomy (OVEX) alone, while MTW9-P regresses rapidly whether or not rats are maintained on perphenazine. Cytosol estradiol binding was determined in MTW9-MtT, in MTW9-P, and in both tumors under different experimental conditions. Values in fmoles/mg protein were: MTW9-MtT, 47.6 ± 3.6 (n = 9), K_d 9.9 ± 2.0 x 10^-11 M; MTW9-P, 195.5 ± 9.1 (n = 16), K_d 27.6 ± 4.7 x 10^-11 M; MTW9-P after perphenazine was withdrawn, 86.0 ± 6.0 (n = 6), K_d 9.9 ± 1.5 x 10^-11 M. Eight S and 4 S peaks were found in cytosols from both tumors by sucrose gradient centrifugation; the peaks differ qualitatively and quantitatively. The possibility that differences in binding levels result from sites filled with endogenous estradiol was critically examined and rejected. Withdrawal of perphenazine results in reduction of estradiol binding but retention of response to OVEX. Hence, response of MTW9-P to OVEX cannot be explained by the 3- to 4-fold increase in estradiol binding over MTW9-MtT. The relationship between estradiol binding and response to OVEX is under study using both mammary tumor models.

¹ This investigation was supported by USPHS Research Grants CA5215, CA14194, and CA10064.

² To whom requests for reprints should be addressed.

Received 11/11/75. Accepted 3/ 1/77.